Heart failure & cardiomyopathiesSecondary analysis
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
- Secondary analysis of the SEQUOIA-HCM randomised trial
- pre-specified analysis
Authors' conclusion
N-Terminal pro-B-type natriuretic peptide and hs-cTnI concentrations are associated with key variables in obstructive hypertrophic cardiomyopathy. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.
Study context
- Population
- Obstructive hypertrophic cardiomyopathy
- Comparison
- Aficamten effect on cardiac biomarkers
Primary result
As reported in the abstract
NT-proBNP and hs-cTnI with aficamten · Within 8 weeks
NT-proBNP reduced by 79% (95% CI 76%-83%)
P < .001
High-sensitivity cardiac troponin I (hs-cTnI) reduced by 41% (95% CI 32%-49%)
P < .001
Further findings
Biomarker reductions and clinical change · 24 weeks
- Reductions in NT-proBNP and hs-cTnI strongly associated with lower left ventricular outflow tract gradient (LVOT-G), improved health status and increased peak oxygen uptake
- NT-proBNP reduction strongly correlated with most improvements in exercise capacity
- Change in NT-proBNP by Week 2 associated with 24-week change in key endpoints
Original publication
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae590
Summarised from the published abstract; every number is checked against it